The US Food and Drug Administration has approved oveporexton, an oral medication marketed as Orzeyful that targets the underlying biological cause of narcolepsy, Nature reported.
The drug functions as an orexin agonist, mimicking a peptide produced by roughly 70,000 neurons in the brain's hypothalamus. In people with type 1 narcolepsy, those cells die off, leaving the brain unable to regulate sleep and wake cycles. Takeda Pharmaceuticals America, based in Cambridge, Massachusetts, identified the candidate compound in 2011 after screening its chemical database.
Trial results and mechanism
Takeda evaluated the drug in two phase III clinical trials enrolling 273 people with type 1 narcolepsy. Participants received either a twice-daily oral dose or a placebo. Across both trials, patients taking Orzeyful showed improvements in daytime wakefulness, nighttime sleep stability, and reductions in sleep paralysis, hallucinations, and cataplexy—a sudden loss of muscle control often triggered by strong emotions.
Emmanuel Mignot, a sleep medicine specialist at Stanford University who led the late-stage trials, noted that the treatment allows patients to experience normal wakefulness. Narcolepsy affects approximately 3 million people worldwide across two forms. While type 1 involves orexin loss and cataplexy, type 2 is not linked to an orexin deficiency, and researchers continue to investigate its origin.
Pipeline and market outlook
Other pharmaceutical companies are pursuing similar mechanisms. Barry Lubarsky, vice-president of medical affairs at Dublin-based Alkermes, confirmed that the company is developing its own narcolepsy treatment. Analysts project the annual market for orexin-targeting therapies to exceed US$6.4 billion by the early 2030s, with researchers investigating whether orexin agonists could also treat other neuropsychiatric conditions.
